MANF Therapeutics Announces the Issuance of U.S. Patent #9,891,231
Allowed claims include the treatment of Type 1 and Type 2 Diabetes Patent protects exclusivity for MANF in diabetes inthe US into 2032 SAN FRANCISCO, March 01, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- MANF Therapeutics, a wholly-owned subsidiary of …